- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2019–2024 · program · P01
Samples and Models Core
Steven Horwitz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · program · P01
Immune manipulation to generate tumor immunity and regulate GVHD after allogeneic HCT
Robert Jon Soiffer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · program · P01
Single Cell and Immunogenomics
Kenneth James Livak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2025 · program · P01
Antigenic basis of immune responses after immune modulatory therapies post-HCT
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · program · P01
Molecular Pathology and Genomics Core
Jon C. Aster · Dana-Farber Cancer Institute · funded by National Institutes of Health
2019–2024 · program · P01
Molecular Pathology and Genomics Core
Jon C. Aster · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
EZH2 in cancer biology and novel inhibitors
Jun Qi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018 · award
Noninvasive imaging of tumor microenvironment as a predictive tool
Mohammad Rashidian · Dana-Farber Cancer Institute · funded by American Cancer Society
2018–2023 · research · R37
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Andrew A Lane · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
Robert J Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K08
Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational Oncology
David Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · grant · KCRP
Is VISTA:VSIG3 an Actionable Immune Checkpoint Target in Kidney Cancer?
Kathleen Mahoney · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2023 · cooperative agreement · U2C
The Cellular Geography of Therapeutic Resistance in Cancer
Bruce E. Johnson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · award
Understanding SMAD4-loss Driven Pancreatic Cancer Metastasis
Chao Dai · Dana-Farber Cancer Institute · funded by American Cancer Society
2018–2023 · career development · K08
Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapy
Yana Pikman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K07
Obesity and Pancreatic Cancer Progression and Survival
Ana Babic · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R01
Degrading therapeutically important kinases using small molecules
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · cooperative agreement · U01
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
Robert J Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R37
Molecular origins and evolution to chemoresistance in germ cell tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018 · research · Postdoc-stipendieprogram inden for endokrinologi/metabolisme ved udenlandske eliteforskningsmiljøer
Metabolite signaling control brown adipocyte thermogenesis
Sally Winther · Dana-Farber Cancer Institute · funded by Novo Nordisk Fonden
2018–2023 · career development · K08
Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapy
Yana Pikman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K00
The Role of E2F2 in HER2 Positive Breast Cancer
Jonathan Rennhack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · research · R35
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Resistance and Sensitivity to MET Inhibitors in Lung Cancer
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
Lawrence Fong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · cooperative agreement · U01
Bioinformatics Technology to Characterize Tumor Infiltrating Immune Repertoires
Xiaole Shirley Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U2C
The Cellular Geography of Therapeutic Resistance in Cancer
Bruce E. Johnson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K07
Obesity and Pancreatic Cancer Progression and Survival
Ana Babic · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · grant · DP1
Identification of Novel Protein Kinases Dependent on Phosphocreatine Rather than ATP
Bruce M. Spiegelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · fellowship · F32
Obesity, Molecular Biomarkers, and Multiple Myeloma Prognosis
Catherine Marinac · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
EZH2 in cancer biology and novel inhibitors
Jun Qi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · grant · DP1
Identification of Novel Protein Kinases Dependent on Phosphocreatine Rather than ATP
Bruce M. Spiegelman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
Tissue-specific genetic interactions in cancer
Kevin Haigis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · cooperative agreement · UG3
Improving Advance Care Planning in Oncology: A Pragmatic, Cluster-Randomized Trial Integrating Patient Videos and Clinician Communication Training
James A. Tulsky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Tissue-specific genetic interactions in cancer
Kevin Haigis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K01
Coordinate roles of histone H3K27me3 and DNA methylation in intestinal homeostasis and tumorigenesis
Unmesh Jadhav · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Hematopoietic stem cell gene therapy for infantile neuronal ceroid lipofuscinosis
Christian Brendel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · cooperative agreement · U01
Bioinformatics Technology to Characterize Tumor Infiltrating Immune Repertoires
Xiaole Shirley Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
